Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine

Journal of Bone and Mineral Research

Volumn 12, Issue 1, 1997, Pages 72-77

  Marcocci, Claudio ^a,b   Golia, Franco ^a   Vignali, Edda ^a   Pinchera, Aldo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Istituto di Endocrinologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; LEVOTHYROXINE; LIOTHYRONINE; OSTEOCALCIN; PARATHYROID HORMONE; SEX HORMONE BINDING GLOBULIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; GOITER; HORMONE INHIBITION; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; THYROID CANCER; THYROIDECTOMY; THYROTOXICOSIS; THYROTROPIN RELEASE;

ADULT; ALKALINE PHOSPHATASE; BONE DENSITY; DENSITOMETRY, X-RAY; FEMUR; FEMUR NECK; GOITER; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROCOLLAGEN; RADIOIMMUNOASSAY; SEX HORMONE-BINDING GLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0031035012     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1997.12.1.72     Document Type: Article

References (43)

1. Mosekilde L, Eriksen EF, Charles P 1990 Effects of thyroid hormones on bone and mineral metabolism, Endocrinol Metab Clin North Am 19:35-63.
2. Eriksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379-408.
3. Toh SH, Claunch BC, Brown PH 1985 Effect of hyperthyroidism and its treatment on bone mineral content. Arch Intern Med 145:883-886.
4. Lee MS, Kim SY, Lee CM, Cho BY, Lee HK, Koh C, Min HK 1990 Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J Clin Endocrinol Metab 70:766-770.
5. Marcocci C, Catalane F, Schipani E, Cetani F, Bruno-Bossio G, Merante C, Pinchera A 1990 Effects of thyrotoxicosis and long-term levothyroxine therapy on appendicular bone density in premenopausal women. In: De Bastiani G, Pecile A, Pietrogrande V, Torri G (eds.) Osteoporoses and Their Treatment. Monduzzi Editore, Bologna, Italy, pp. 37-43.
6. Fraser SA, Anderson JB, Smith DA, Wilson GM 1971 Osteoporosis and fractures following thyrotoxicosis. Lancet 1:981-983.
7. Gumming SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM 1995 Risk factors for hip fracture in white women. New Engl J Med 332:767-773.
8. Ross DS 1991 Editorial: Monitoring L-thyroxine therapy: Lesson from the effects of L-thyroxine on bone density. Am J Med 91:1-4.
9. Baran TB 1994 Editorial: Detrimental skeletal effects of thyrotropin suppressive doses of thyroxine: Fact or fantasy? J Clin Endocrinol Metab 78:816-817.
10. Burman DK 1995 How serious are the risks of thyroid hormone over-replacement? Thyroid Today 18:1-4.
11. Ross DS, Neer RM, Ridgway EC, Daniels GH 1987 Subclinical hyperthyroidsm and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 82:1167-1170.
12. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT 1988 Long-term L-thyroxine is associated with decreased hip bone density in premenopausal women. JAMA 259:3137-3141.
13. Diamond T, Nery L, Hales Y 1990 A therapeutic dilemma: Suppressive doses of thyroxine reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 72:1184-1188.
14. Pioli G, Pedrazzoni M, Palummeri E, Sianesi M, Del Frate R, Vescovi PP, Prisco M, Ulietti V, Costi D, Passed M 1992 Longitudinal study of bone loss after thyroidectomy and suppressive therapy in premenopausal women. Acta Endocrinol (Copenhagen) 126:238-242.
15. Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AL, Genant HK 1991 Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am J Med 91:5-14.
16. Franklin JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Lilley J, Heath DA, Sheppard MC 1992 Long-term thyroxine treatment and bone mineral density. Lancet 340:2-13.
17. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A 1994 Carefully monitored levothyroxine therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78:818-823.
18. Duncan W, Chang A, Solomon B, Wartofsky L 1994 Influence of clinical characteristics and parameters associated with thyroid hormone therapy on bone mineral density of women treated with thyroid hormone. Thyroid 4:183-190.
19. Orwoll ES, Klein RF 1995 Osteoporosis in men. Endocr Rev 16:87-116.
20. Bartalena L, Pinchera A 1994 Levothyroxine suppressive therapy: Harmful and useless or harmless and useful? J Endocrinol Invest 17:675-677.
21. Romelli PB, Pennisi F, Vancheri L 1979 Measurement of free thyroid hormones in serum by column adsorption chromatography and radioimmunoassay. J Endocrinol Invest 2:25-40.
22. Ekins R 1990 Measurement of free hormones in blood. Endocr Rev 11:5-46.
23. Rosner W, Aden DP, Khan MS 1984 Hormonal influences on the secretion of steroid-binding proteins by a human hepatoma-derived cell line. J Clin Endocrinol Metab 59:806-809.
24. Toft AD 1994 Thyroxine therapy. New Engl J Med 331: 174-180.
25. Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW 1995 A therapeutic controversy. Thyroid hormone treatment: When and what? J Clin Endocrinol Metab 80: 2873-2883.
26. Mazzaferri EL 1987 Papillary thyroid carcinoma: Factors influencing prognosis and current therapy. Semin Oncol 14:315-332 (erratum, Semin Oncol 1988, 15:x).
27. Cooper DS 1995 Thyroxine suppression therapy for benign nodular disease. J Clin Endocrinol Metab 80:331-334.
28. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, Saccà L, Bellastella A, Lombardi G 1993 Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334-338.
29. Biondi S, Fazio B, Carella C, Sabatini D, Cittadini A, Panza N, Lombardi G, Saccà L1995 Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: Beneficial effect of b-blocade. J Clin Endocrinol Metab 80:2222-2226.
30. Ladenson PW 1993 Editorial: Thyrotoxicosis and the heart: Something old and something new. J Clin Endocrinol Metab 77:332-333.
31. Faber J, Galloe A 1994 Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis. Eur J Endocrinol 130:350-356.
32. Schneider DL, Barret-Connor EL, Morton DJ 1994 Thyroid hormone use and bone mineral density in elderly women. JAMA 271:1245-1249.
33. Leese GP, Jung RT, Guthrie C, Waugh N, Browing MCK. 1992 Morbidity in patients on L-thyroxine: A comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxford) 37:500-504.
34. Solomon BL, Wartofsky L, Burman KD 1993 Prevalence of fractures in postmenopausal women with thyroid diseases. Thyroid 3:17-23.
35. McDermott MT, Kidd GS, Blue P, Ghead V, Hofeldt FD 1983 Reduced bone mineral content in totally thyroidectomized patients: Possible effect of calcitonin deficiency. J Clin Endocrinol Metab 56:936-939.
36. Hurley DL, Tiegs RD, Wahner HW, Heath H III 1987 Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. New Engl J Med 317:537-541.
37. Gonzales DC, Mautalen CA, Correa PH, El Tamer E, El Tamer S 1991 Bone mass in totally thyroidectomized patients: Role of calcitonin deficiency and exogenous thyroid treatment. Acta Endocrinol (Copenhagen) 124:521-552.
38. Ross DR, Ardisson LJ, Nussbaum SR, Meskell MJ 1991 Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J Clin Endocrinol Metab 72:507-509.
39. Harvey RD, McHardy KC, Reid IW, Paterson F, Bewsher PD, Duncan A, Robins SP 1991 Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J Clin Endocrinol Metab 72:1189-1194.
40. Stepan JJ, Limanova Z 1992 Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. Bone Miner 17:377-388.
41. L Marcocci C, Golia F, Vignali E, Bruno-Bossio G, Picone A, Puccinelli S, Bonacci R, Pinchera A 1993 Thyroid hormone therapy and bone mass: Prospective studies. J Bone Miner Res 10(Suppl 1):S385 (abstract).
42. Burman KD 1990 Is long-term levothyroxine therapy safe? Arch Intern Med 150:2010-2013.
43. Utiger RD 1990 Therapy of hypothyroidism: When are changes needed? New Engl J Med 323:126-127.